Clinical/Research Interests

Specialty:

Center/Program Affiliation:

Address:

Phone:

Education:

Internships:

Residency:

Fellowships:

Board Certifications:

Professional Memberships:

Select Recent Publications:

Rubin D, T Albertson, C Richman. Intensive care unit admissions in patients with hematologic malignancies: Outcomes and prognostic indicators. Abstract presented at the 47th Annual Meeting of the American Society of Hematology. Blood, 106(11):Abstract # 752.

DeNardo SJ, CM Richman, H Albrecht, PA Burke, A Natarajan, A Yuan, GP Gregg, RT O'Donnell, GL DeNardo. Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clinical Cancer Research, 11(19 Suppl):7187s-7194s.

Miers L, K Lamborn, A Yuan, C Richman, A Natarajan, S DeNardo, G DeNardo. Does paclitaxel given after 111In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? Clinical Cancer Research, 11(19 Suppl):7158s-7163s.

Shen S, SJ DeNardo, CM Richman, A Yuan, C Hartmann Siantar, RT O'Donnell, GL DeNardo. Planning time for peripheral blood stem cell transfusion after high-dose targeted radionuclide therapy using dosimetry. Journal of Nuclear Medicine, 46(6):1034-1041.

Richman CM, SJ DeNardo, RT O'Donnell, A Yuan, DS Goldstein, S Shen, JM Tuscano, T Wun, HK Chew, PN Lara, DL Kukis, A Natarajan, CG Meares, KR Lamborn, GL DeNardo. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent HAMA. Clinical Cancer Research, 11(16):5920-5927.

Rodler E, J Welborn, S Hatcher, K Unger, E Larkin, P Gumerlock, T Wun, C Richman. Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature. American Journal of Hematology, 75:231-238.

Martel CL, Y Li, L Beckett, H Chew, S Christensen, A Davies, KS Lam, DH Lau, FJ Meyers, R O'Donnell, C Richman, S Scudder, M Tanaka, J Tuscano, J Welborn, T Wun, DR Gandara, PN Lara. Cancer clinical trial accrual patterns: A prospective re-evaluation of barriers to enrollment following passage of legislation requiring third-party payer coverage of cancer clinical trial costs in California. The Cancer Journal, 10(5):294-300.

Wang H, LJ Laslett, CM Richman, T Wun. Acute myocardial infarction in hemoglobin SC disease. Annals of Hematology, 83(10):622-624.

DeNardo G, A Yuan, D Goldstein, C Richman, R O'Donnell, S Shen, C Siantar, S DeNardo. Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled Mabs. Cancer Biotherapy and Radiopharmaceuticals. 18(2):231-237.

DeNardo SJ, GL DeNardo, A Yuan, CM Richman, RT O'Donnell, PN Lara, DL Kukis, A Natarajan, KR Lamborn, F Jacobs, CL Hartmann Siantar. Enhanced therapeutic index of radioimmunotherapy in prostate cancer patients: Comparison of radiation dosimetry for DOTA-peptide versus 2IT-DOTA Mab linkage for RIT. Clinical Cancer Research (Supplement), 9:3938s-3944s.